凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花生物:2014年第三季度报告

公告日期 2014-10-28
股票简称:梅花生物 股票代码:600873
梅花生物科技集团股份有限公司
           600873
    2014 年第三季度报告
                             梅花生物 2014 年第三季度报告
                                     目录一、重要提示 .................................................................... 3二、公司主要财务数据和股东变化 ............................................... 3三、重要事项 .................................................................... 6四、附录 ....................................................................... 11
                                        2 / 22
                                   梅花生物 2014 年第三季度报告一、 重要提示1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,
    不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。1.2 公司全体董事出席董事会审议季度报告。1.3 公司负责人孟庆山、主管会计工作负责人李勇刚及会计机构负责人(会计主管人员)陶忠保
    证季度报告中财务报表的真实、准确、完整。1.4 本公司第三季度报告未经审计。二、 公司主要财务数据和股东变化2.1 主要财务数据
                                                                           单位:元    币种:人民币
                                                                            本报告期末比上年度末增
                      本报告期末                       上年度末
                                                                                      减(%)
    总资产              19,717,136,133.53                  18,713,590,263.14                         5.36
    归属于上市公司股     7,987,544,156.19                   8,027,109,018.71                       -0.49东的净资产
                    年初至报告期末            上年初至上年报告期末
                                                                              比上年同期增减(%)
                      (1-9 月)                   (1-9 月)
    经营活动产生的现       551,436,190.63                     713,455,223.11                      -22.71金流量净额
                    年初至报告期末            上年初至上年报告期末              比上年同期增减
                      (1-9 月)                   (1-9 月)                         (%)
    营业收入             7,276,815,615.07                   5,855,259,321.17                       24.28归属于上市公司股
                       271,257,797.78                     274,834,322.30                       -1.30东的净利润归属于上市公司股
    东的扣除非经常性       189,326,996.50                     164,153,852.59                       15.34损益的净利润加权平均净资产收
                                    3.39                            3.86      增加    -0.47 个百分点益率(%)基本每股收益(元/
                                    0.09                            0.09                            0股)稀释每股收益(元/
                                    0.09                            0.09                            0股)扣除非经常性损益项目和金额
                                                                           单位:元    币种:人民币
                                              3 / 22
                                      梅花生物 2014 年第三季度报告
                                                                 本期金额           年初至报告期末       说明
                          项目
                                                              (7-9 月)           金额(1-9 月)
    非流动资产处置损益                                            -2,345,495.76           -7,824,485.26越权审批,或无正式批准文件,或偶发性的税收返还、减免
    计入当期损益的政府补助,但与公司正常经营业务密切相关,        27,101,860.25           92,802,923.27符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外
    除同公司正常经营业务相关的有效套期保值业务外,持有交             1,011,216.53          4,180,886.59易性金融资产、交易性金融负债产生的公允价值变动损益,以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益
    除上述各项之外的其他营业外收入和支出                             1,700,106.11          2,584,989.95其他符合非经常性损益定义的损益项目
    所得税影响额                                                      -302,959.85         -9,813,513.27少数股东权益影响额(税后)
                          合计                                27,164,727.28           81,930,801.282.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
                                                                                                        单位:股
                 股东总数(户)                                                    61481
                                           前十名股东持股情况
                                                          持有有限            质押或冻结情况            股东性质
    股东名称       报告期内增       期末持股数   比例
                                                          售条件股
    (全称)           减               量        (%)                    股份状态               数量
                                                           份数量
                                                                                                        境内自然
    孟庆山                           854,103,033   27.48         0              质押       784,590,000
                                                                                                            人
                                                                                                        境内自然
    胡继军                           369,394,122   11.88         0              质押       369,390,000
                                                                                                            人香港鼎晖生物
                 -38,000,000     203,625,120   6.55          0               无                         境外法人科技有限公司新天域生化科
    技投资有限公                     169,106,616   5.44          0               无                         境外法人司建信基金公司-慧智投资 8
                                 111,640,000   3.59          0               无                           其他号结构化集合资金信托计划
                                                                                                        境内自然
    杨维永                            78,810,526   2.54          0              质押           78,810,526
                                                                                                            人
                                                                                                        境内自然
    王爱军                            71,316,274   2.29          0              质押           71,316,274
                                                                                                            人昆明盈鑫叁壹
    投资中心(有                      63,800,000   2.05          0               无                           其他限合伙)云南国际信托
    有限公司-瑞     -8,685,984       61,516,499   1.98          0               无                           其他鸿 2014-23 号
                                                                                                        境内自然
    李宝骏                            58,020,019   1.87          0              质押           56,690,000
                                                                                                            人
                                                 4 / 22
                                    梅花生物 2014 年第三季度报告
                                    前十名无限售条件股东持股情况
    股东名称                                  持有无限售条件流通股的数              股份种类及数量
                                                     量                      种类                数量
    孟庆山                                                    854,103,033    人民币普通股       854,103,033
    胡继军                                                    369,394,122    人民币普通股       369,394,122
    香港鼎晖生物科技有限公司                                  203,625,120    人民币普通股       203,625,120
    新天域生化科技投资有限公司                                169,106,616    人民币普通股       169,106,616建信基金公司-慧智投资 8 号结构化集合
                                                          111,640,000    人民币普通股       111,640,000资金信托计划
    杨维永                                                     78,810,526    人民币普通股        78,810,526
    王爱军                                                     71,316,274    人民币普通股        71,316,274
    昆明盈鑫叁壹投资中心(有限合伙)                           63,800,000    人民币普通股        63,800,000
    云南国际信托有限公司-瑞鸿 2014-23 号                     61,516,499    人民币普通股        61,516,499
    李宝骏                                                     58,020,019    人民币普通股        58,020,019
    上述股东关联关系或一致行动的说明         上述股东中,孟庆山、杨维永、王爱军为一致行动人,其持有的股份
                                         已追加承诺,自 2014 年 1 月 2 日上市流通之日起追加限售锁定期 24
                                         个月,即自 2014 年 1 月 2 日起 24 个月不上市交易或转让。
    表决权恢复的优先股股东及持股数量的说     无明
                                                5 / 22
                                                            梅花生物 2014 年第三季度报告三、 重要事项3.1 公司主要会计报表项目、财务指标重大变动的情况及原因√适用 □不适用
    资产负债表项目:                                                                                                                      单位:万元
                                                            增 减 幅
    项目                 本报告期末   上年度期末   增减额                  差异说明
                                                            度%
    交易性金融资产       4,500.00                  4,500.00     100.00     本期购买理财产品
    应收账款                                                               主要为本期新增合并主体增加应收账款以及本期销售收入增加、味精、氨基酸客户授信增加
                     47,394.09    19,920.42    27,473.67    137.92
                                                                       所致
    预付款项             93,179.07    33,895.91    59,283.16    174.90     主要为本公司子公司通辽梅花生物科技有限公司竞拍玉米预付款增加所致
    其他流动资产         53,718.73    83,506.77    -29,788.04   -35.67     主要为本期预交税款减少所致
    工程物资             816.66       3,125.82     -2,309.16    -73.87     本期工程项目减少所致
    商誉                                                                   本期子公司拉萨梅花生物控股有限公司收购大连汉信生物制药有限公司及山西广生医药包装
                     40,777.99    1,178.89     39,599.10    3,359.02
                                                                       股份有限公司,收购价款与收购日净资产公允价值差异形成商誉增加
    递延所得税资产       810.90       532.56       278.34       52.26      本期计提坏账准备增加所致
    其他非流动资产       20,000.00    56,543.16    -36,543.16   -64.63     主要系本期股权收购完成原预付股权收购款已转入长期股权投资科目核算
    应付票据             800.00       13,276.00    -12,476.00   -93.97     本期票据到期承付增加所致
    预收款项             38,271.69    67,636.89    -29,365.20   -43.42     主要是面对激烈的市场竞争为扩大销售,减少预收款的销售方式所致
    应付职工薪酬         4,891.72     3,406.37     1,485.35     43.61      本期新增合并主体所致
    应交税费             8,723.60     2,880.17     5,843.43     202.88     本期新增合并主体所致
    应付利息             18,126.77    8,792.67     9,334.10     106.16     本期新增短期融资劵利息增加所致一年内到期的非流动
                     40,155.00    100,000.00   -59,845.00   -59.85     本期 6 亿长期借款到期已偿还负债
    其他流动负债         299,690.34   99,720.02    199,970.32   200.53     本期发行两期共 20 亿短期融资券
                                                                       6 / 22
                                                               梅花生物 2014 年第三季度报告
    长期借款             146,999.79   100,000.00       46,999.79   47.00        本期长期融资业务增加所致
    预计负债                          110.00           -110.00     -100.00      本期已支付完毕
    少数股东权益         15,868.31                     15,868.31   100.00       本期收购山西广生医药包装股份有限公司 51.761%股权产生少数股权权益利润表项目:
                                                               增 减 幅
    项目                 本报告期     上年同期         增减额                   差异说明
                                                               度%
    营业税金及附加       1,873.56     2,680.91         -807.35     -30.11       本期流转税减少导致计提城建税及教育费附加减少所致
    财务费用             31,943.37    13,834.96        18,108.41   130.89       本期子公司新疆梅花氨基酸有限责任公司部分项目转固,利息支出由资本化转为费用化支出
    资产减值损失         725.76       332.17           393.59      118.49       本期计提坏账准备增加所致
    投资收益             322.36       230.25           92.11       40.00        本期理财收益增加所致
    营业外支出           833.68       240.44           593.24      246.73       本期处置固定资产清理损失增加所致
    所得税费用           3,701.28     6,951.26         -3,249.98   -46.75       本期利润减少导致计提所得税费用减少现金流量项目:
                  项目                          本报告期             上年同期                增减额            增减幅度%                差异说明
    投资活动产生的现金流量净额                     -66,379.70        -144,895.69             78,515.99               54.19     主要系本期购建资产投入资金减少所致
    筹资活动产生的现金流量净额                     26,744.86             97,152.99          -70,408.13              -72.47     主要系本期吸收投资收到款项减少所致
                                                                             7 / 22
                                   梅花生物 2014 年第三季度报告3.2 重要事项进展情况及其影响和解决方案的分析说明□适用 √不适用3.3 公司及持股 5%以上的股东承诺事项履行情况√适用 □不适用
                                                                         承诺时     是否有   是否及
    承诺   承诺
                  承诺方                   承诺内容                      间及期     履行期   时严格
    背景   类型
                                                                             限       限     履行
                           在孟庆山先生及一致行动人作为上市公司控
                           股股东或实际控制人之期限内,将采取有效
                                                                        2010 年 7
        解决   孟庆山及    措施,并促使孟庆山先生或孟庆山先生及一
                                                                        月 19 日
        同业   其一致行    致行动人下属控股子公司采取有效措施,不                     否      是
                                                                        出具承
        竞争   动人        会从事或参与任何可能对上市公司或其控股
                                                                        诺
                           子公司目前主要从事的业务构成竞争的业
                           务。与重
                           在本次交易完成后继续保持上市公司的独立       2010 年 7
    大资          孟庆山及
                           性,在资产、人员、财务、机构、业务上遵       月 19 日
    产重   其他   其一致行                                                               否      是
                           循五分开原则,遵守中国证监会有关规定,       出具承
    组相          动人
                           规范运作上市公司。                           诺关的
                           在重组完成后,孟庆山先生及一致行动人将承诺
                           尽量避免与上市公司的关联交易,若有不可
                           避免的关联交易,孟庆山先生及一致行动人       2010 年 7
        解决   孟庆山及
                           与上市公司将依法签订协议,履行合法程序, 月 19 日
        关联   其一致行                                                               否      是
                           并将按照有关法律、法规、《公司章程》等       出具承
        交易   动人
                           有关规定履行信息披露义务和办理有关报批       诺
                           事宜。保证不通过关联交易损害上市公司及
                           其他股东的合法权益。
               股东孟庆    上述五人持有的公司股份自 2014 年 1 月 2 日   24 个月,
               山、杨维    上市流通之日起追加限售锁定期 24 个月,即     2014 年 1
    其他   股份
               永、王爱    自 2014 年 1 月 2 日起 24 个月不上市交易或   月2日         是      是
    承诺   限售
               军、何君、 转让,限售期满后按照中国证监会或上海证        -2016 年
               杨维英      券交易所的有关规定执行。                     1月2日3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警
    示及原因说明□适用 √不适用
                                                8 / 22
                                 梅花生物 2014 年第三季度报告3.5 执行新会计准则对合并财务报表的影响
    1.执行《企业会计准则第 9 号—职工薪酬》、《企业会计准则第 30 号—财务报表列报》、《企业会计准则第 33 号-合并财务报表》、《企业会计准则第 39 号—公允价值计量》、《企业会计准则第 40 号—合营安排》、《企业会计准则第 41 号—在其他主体中权益的披露》、《企业会计准则第 37 号—金融工具列报》的相关情况:新准则的实施不会对公司 2013 年度及本期财务报表相关项目金额产生影响。
    2.执行《企业会计准则第 2 号—长期股权投资》对合并财务报告的影响详见“3.5.1 长期股权投资准则变动对于合并财务报告影响(一)”3.5.1 长期股权投资准则变动对于合并财务报告影响(一)
                                                                     单位:元     币种:人民币
                            2013年1月1日归                      2013年12月31日
    被投资       交易基本
                            属于母公司股东     长期股权投资     可供出售金融资    归属于母公司股
      单位         信息
                              权益(+/-)        (+/-)          产(+/-)       东权益(+/-)
    西藏银行股份有   股权比例                      -45,000,000.00     45,000,000.00
    限公司           为 3%
    合计                                      -45,000,000.00     45,000,000.00长期股权投资准则变动对于合并财务报告影响(一)的说明
    根据《财政部关于印发修订<企业会计准则第2号—长期股权投资>的通知》 财会[2014]14 号)中对持有的不具有控制、共同控制、重大影响的股权投资,不作为长期股权投资核算,应作为可供出售金融资产进行核算,本期将公司对西藏银行股份有限公司3%股权投资调整为可供出售金融资产核算,对其采用追溯调整法进行调整。3.5.2 其他
    1.2014 年 7 月,公司接西藏银行通知获悉,西藏银行拟实行转增股本并增资扩股事项:西藏银行以总股本 15 亿股为基数,向全体股东每 15 股转增 1 股,共转增 1 亿股,转增完成后西藏银行股本总数为 16 亿股;与此同时,西藏银行拟采用非公开方式发行不超过 16 亿股(含),每股1.4 元。上述转增股本并增资扩股完成后,西藏银行注册资本将由 15 亿元变为 32 亿元。
    截止本报告出具日,公司已与西藏银行签署了股份认购协议,公司认购西藏银行新发行股份4800 万股,每股 1.4 元,认购额 6720 万元,认购完成后,公司将持有西藏银行 9600 万股股份,仍占该行股本总数的 3%。
                                             9 / 22
                               梅花生物 2014 年第三季度报告
    2.因筹划发行股份购买资产事项,公司股票于 2014 年 8 月 26 日开市起停牌。经与交易各方协商,初步拟定了交易方案:公司拟通过发行股份购买资产的方式收购行业内一家生物发酵企业,并向不超过十名特定投资者非公开发行股份募集配套资金。停牌期间,公司和交易各方以及中介机构积极推进本次发行股份购买资产事宜相关工作,包括尽职调查、审计、评估等,并与交易对方就交易方案细节进行进一步完善和确认。
    停牌期间,公司将根据交易进展情况,及时履行信息披露义务,每五个交易日发布一次有关事项的进展情况公告,待相关工作完成后召开董事会审议预案,及时公告并复牌。
                                                     公司名称    梅花生物科技集团股份有限公司
                                                    法定代表人             孟庆山
                                                       日期              2014-10-27
                                         10 / 22
                                梅花生物 2014 年第三季度报告四、 附录4.1 财务报表
                                    合并资产负债表
                                   2014 年 9 月 30 日编制单位:梅花生物科技集团股份有限公司
                                               单位:元    币种:人民币   审计类型:未经审计
               项目                      期末余额                        年初余额流动资产:
    货币资金                                 1,287,417,104.54                 1,216,617,968.54
    结算备付金
    拆出资金
    交易性金融资产                              45,000,000.00
    应收票据                                   163,089,778.92                   157,885,031.98
    应收账款                                   473,940,918.99                   199,204,239.81
    预付款项                                   931,790,738.60                   338,959,094.26
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                 518,460,065.37                   410,948,756.66
    买入返售金融资产
    存货                                     1,397,625,270.46                 1,637,414,459.98
    一年内到期的非流动资产
    其他流动资产                               537,187,334.14                   835,067,662.75
    流动资产合计                           5,354,511,211.02                 4,796,097,213.98非流动资产:
    发放委托贷款及垫款
    可供出售金融资产                            45,000,000.00                   45,000,000.00
    持有至到期投资
    长期应收款
    长期股权投资                                75,641,468.17                   76,598,769.04
    投资性房地产
    固定资产                                11,224,081,854.05                10,636,584,947.54
                                          11 / 22
                            梅花生物 2014 年第三季度报告
    在建工程                             1,520,759,458.80   1,828,904,737.50
    工程物资                                 8,166,584.11      31,258,164.87
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                               873,086,690.61     716,600,248.92
    开发支出
    商誉                                   407,779,857.90      11,788,911.79
    长期待摊费用
    递延所得税资产                           8,109,008.87       5,325,638.51
    其他非流动资产                         200,000,000.00     565,431,630.99
    非流动资产合计                    14,362,624,922.51   13,917,493,049.16
       资产总计                        19,717,136,133.53   18,713,590,263.14流动负债:
    短期借款                             3,427,279,731.60   4,213,045,728.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                                 8,000,000.00     132,760,000.00
    应付账款                               889,539,844.28     990,782,105.29
    预收款项                               382,716,923.77     676,368,865.16
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                            48,917,188.04      34,063,713.31
    应交税费                                87,235,977.96      28,801,688.79
    应付利息                               181,267,665.33      87,926,721.10
    应付股利
    其他应付款                            714,238,110.01      567,598,726.11
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债                 401,550,000.00   1,000,000,000.00
    其他流动负债                         2,996,903,443.55     997,200,241.92
                                      12 / 22
                                   梅花生物 2014 年第三季度报告
    流动负债合计                              9,137,648,884.54                8,728,547,789.68非流动负债:
    长期借款                                    1,469,997,910.00                1,000,000,000.00
    应付债券                                      895,835,813.33                  893,816,933.66
    长期应付款
    专项应付款
    预计负债                                                                       1,100,000.00
    递延所得税负债
    其他非流动负债                                 67,426,301.84                   63,016,521.09
    非流动负债合计                            2,433,260,025.17                1,957,933,454.75
       负债合计                               11,570,908,909.71               10,686,481,244.43所有者权益(或股东权益):
    实收资本(或股本)                          3,108,226,603.00                3,108,226,603.00
    资本公积                                    2,240,485,918.58                2,240,485,918.58
    减:库存股
    专项储备
    盈余公积                                      178,950,228.74                  178,950,228.74
    一般风险准备
    未分配利润                                  2,459,881,405.87                2,499,446,268.39
    外币报表折算差额
    归属于母公司所有者权益合计                  7,987,544,156.19                8,027,109,018.71
    少数股东权益                                  158,683,067.63
    所有者权益合计                            8,146,227,223.82                8,027,109,018.71
       负债和所有者权益总计                   19,717,136,133.53               18,713,590,263.14
    法定代表人:孟庆山            主管会计工作负责人:李勇刚          会计机构负责人:陶忠
                                             13 / 22
                                梅花生物 2014 年第三季度报告
                                   母公司资产负债表
                                   2014 年 9 月 30 日编制单位:梅花生物科技集团股份有限公司
                                               单位:元     币种:人民币 审计类型:未经审计
               项目                      期末余额                       年初余额流动资产:
    货币资金                                   313,261,824.15                  459,982,912.10
    交易性金融资产
    应收票据                                   127,526,586.27                   63,999,952.60
    应收账款                                   184,623,386.07                  207,667,769.18
    预付款项                                   315,730,167.77                  193,404,177.05
    应收利息
    应收股利                                   300,000,000.00                  300,000,000.00
    其他应收款                               7,673,035,566.12                6,346,952,981.20
    存货                                       141,329,745.16                  206,711,681.78
    一年内到期的非流动资产
    其他流动资产                                10,964,892.22                   35,285,857.69
    流动资产合计                           9,066,472,167.76                7,814,005,331.60非流动资产:
    可供出售金融资产                            45,000,000.00                   45,000,000.00
    持有至到期投资
    长期应收款
    长期股权投资                             5,453,641,468.17                5,364,598,769.05
    投资性房地产
    固定资产                                   215,887,474.50                  251,973,880.19
    在建工程                                     1,261,299.14                       1,794,000.00
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                    42,775,686.90                   43,042,034.93
    开发支出
    商誉
    长期待摊费用
    递延所得税资产                                   8,774.68                           8,774.68
    其他非流动资产                             200,000,000.00                  500,000,000.00
    非流动资产合计                         5,958,574,703.39                6,206,417,458.85
                                          14 / 22
                                   梅花生物 2014 年第三季度报告
        资产总计                              15,025,046,871.15                14,020,422,790.45流动负债:
    短期借款                                   1,400,000,000.00                 1,740,000,000.00
    交易性金融负债
    应付票据                                       8,000,000.00                    10,000,000.00
    应付账款                                   1,769,025,906.85                   751,357,018.29
    预收款项                                     226,439,538.03                   390,498,272.59
    应付职工薪酬                                                                      211,582.82
    应交税费                                      34,241,477.66                    16,672,602.71
    应付利息                                     179,316,383.08                    82,573,689.44
    应付股利
    其他应付款                                   282,765,435.35                 1,117,426,557.69
    一年内到期的非流动负债                       400,000,000.00                 1,000,000,000.00
    其他流动负债                               2,996,903,443.55                   997,200,241.92
      流动负债合计                             7,296,692,184.52                 6,105,939,965.46非流动负债:
    长期借款                                   1,000,000,000.00                 1,000,000,000.00
    应付债券                                     895,835,813.33                   893,816,933.66
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债
      非流动负债合计                           1,895,835,813.33                 1,893,816,933.66
        负债合计                               9,192,527,997.85                 7,999,756,899.12所有者权益(或股东权益):
    实收资本(或股本)                         3,108,226,603.00                 3,108,226,603.00
    资本公积                                   2,208,701,622.94                 2,208,701,622.94
    减:库存股
    专项储备
    盈余公积                                     178,950,228.74                   178,950,228.74
    一般风险准备
    未分配利润                                   336,640,418.62                   524,787,436.65
    所有者权益(或股东权益)合计                   5,832,518,873.30                 6,020,665,891.33
      负债和所有者权益(或股东权
                                              15,025,046,871.15                14,020,422,790.45益)总计
    法定代表人:孟庆山           主管会计工作负责人:李勇刚           会计机构负责人:陶忠
                                             15 / 22
                                     梅花生物 2014 年第三季度报告
                                                合并利润表编制单位:梅花生物科技集团股份有限公司
                                                      单位:元      币种:人民币      审计类型:未经审计
                                                                      年初至报告期期      上年年初至报告
                                本期金额             上期金额
           项目                                                           末金额         期期末金额(1-9
                                (7-9 月)          (7-9 月)
                                                                        (1-9 月)             月)
    一、营业总收入               2,665,157,895.18    1,933,750,459.02    7,276,815,615.07    5,855,259,321.17
    其中:营业收入           2,665,157,895.18    1,933,750,459.02    7,276,815,615.07    5,855,259,321.17
           利息收入
           已赚保费手续费及佣金收入
    二、营业总成本               2,543,283,555.02    1,923,507,358.74    7,059,332,009.26    5,636,456,389.94
    其中:营业成本           2,153,686,674.26    1,643,811,805.11    5,944,021,810.21    4,788,806,071.74
           利息支出手续费及佣金支出退保金赔付支出净额提取保险合同准备金净额
           保单红利支出
           分保费用
           营业税金及附加       6,437,475.74         8,551,528.85       18,735,585.46       26,809,068.47
    销售费用                      170,804,677.34       139,374,011.67      486,100,054.36      403,655,089.31
    管理费用                      102,744,200.21        88,414,807.25      283,783,283.30      275,514,896.59
    财务费用                      109,610,637.47        43,355,205.86      319,433,666.54      138,349,571.86
           资产减值损失               -110.00                            7,257,609.39        3,321,691.97
    加:公允价值变动收益(损失以“-”号填列)
      投资收益(损失以
                                 -603,286.02           923,171.73        3,223,585.71        2,302,503.28“-”号填列)
         其中:对联营企业
                               -1,614,502.55          -124,909.25         -957,300.88           42,666.59和合营企业的投资收益
      汇兑收益(损失以“-”号填列)三、营业利润(亏损以“-”
                              121,271,054.14        11,166,272.01      220,707,191.52      221,105,434.51号填列)
                                                  16 / 22
                                   梅花生物 2014 年第三季度报告
    加:营业外收入           28,857,656.22      55,924,243.31      95,900,222.54   125,645,882.69
    减:营业外支出            2,401,185.62       1,562,229.61       8,336,794.58     2,404,377.85
       其中:非流动资产处
                              2,357,350.58          19,529.68       7,916,131.60       233,878.95置损失四、利润总额(亏损总额以
                             147,727,524.74     65,528,285.71     308,270,619.48   344,346,939.35“-”号填列)
    减:所得税费用            8,878,257.11      10,869,946.52      37,012,821.70    69,512,617.05五、净利润(净亏损以“-”
                             138,849,267.63     54,658,339.19     271,257,797.78   274,834,322.30号填列)
    归属于母公司所有者的
                             138,849,267.63     54,658,339.19     271,257,797.78   274,834,322.30净利润
    少数股东损益六、每股收益:
    (一)基本每股收益(元
                                       0.05              0.02               0.09             0.09/股)
    (二)稀释每股收益(元
                                       0.05              0.02               0.09             0.09/股)七、其他综合收益
    八、综合收益总额             138,849,267.63     54,658,339.19     271,257,797.78   274,834,322.30
    归属于母公司所有者的
                             138,849,267.63     54,658,339.19     271,257,797.78   274,834,322.30综合收益总额
    归属于少数股东的综合收益总额
    法定代表人:孟庆山            主管会计工作负责人:李勇刚              会计机构负责人:陶忠
                                              17 / 22
                                     梅花生物 2014 年第三季度报告
                                             母公司利润表编制单位:梅花生物科技集团股份有限公司
                                                   单位:元     币种:人民币        审计类型:未经审计
                                                                    年初至报告期期       上年年初至报告
                                本期金额           上期金额
           项目                                                         末金额          期期末金额(1-9
                                (7-9 月)         (7-9 月)
                                                                       (1-9 月)             月)
    一、营业收入                 1,540,204,773.87   1,135,013,768.80    4,404,889,574.15    2,089,433,450.60
    减:营业成本             1,351,256,455.32   1,053,438,364.07    3,950,657,692.17    1,971,108,319.62
        营业税金及附加          1,423,781.18           41,873.70        3,770,422.08        1,679,952.71
        销售费用               93,312,549.47       80,574,069.91      272,312,453.13      141,010,243.19
        管理费用               26,620,371.84       30,760,132.55       73,940,388.19      107,093,913.09
        财务费用               -7,187,624.90          709,830.98       -2,490,313.67         -153,789.97
        资产减值损失                                                    1,117,626.22        6,314,805.07
    加:公允价值变动收益(损失以“-”号填列)
        投资收益(损失以
                               -1,179,771.30          436,781.16        3,450,769.99          933,055.63“-”号填列)
           其中:对联营企
                               -1,614,502.54         -124,909.25         -957,300.88           42,666.59业和合营企业的投资收益二、营业利润(亏损以“-”
                               73,599,469.66      -30,073,721.25      109,032,076.02     -136,686,937.48号填列)
    加:营业外收入              9,773,776.73       14,280,648.08       13,748,928.62       26,072,203.44
    减:营业外支出                   5,000.00             398.15          105,362.37           81,712.31
    其中:非流动资产处置损失                                    99.39           1,238.33            5,738.45三、利润总额(亏损总额以
                               83,368,246.39      -15,793,471.32      122,675,642.27     -110,696,446.35“-”号填列)减:所得税费用四、净利润(净亏损以“-”
                               83,368,246.39      -15,793,471.32      122,675,642.27     -110,696,446.35号填列)五、每股收益:(一)基本每股收益(元/股)(二)稀释每股收益(元/股)六、其他综合收益
    七、综合收益总额               83,368,246.39      -15,793,471.32      122,675,642.27     -110,696,446.35
    法定代表人:孟庆山              主管会计工作负责人:李勇刚             会计机构负责人:陶忠
                                                18 / 22
                                    梅花生物 2014 年第三季度报告
                                    合并现金流量表
                                    2014 年 1—9 月编制单位:梅花生物科技集团股份有限公司
                                            单位:元           币种:人民币    审计类型:未经审计
               项目                     年初至报告期期末金额           上年年初至报告期期末金额(1-9
                                             (1-9月)                             月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                6,548,725,197.27                   5,789,655,375.12客户存款和同业存放款项净增加额
    向中央银行借款净增加额向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                  28,436,696.23                        51,599,055.99
    收到其他与经营活动有关的现金                   146,735,807.26                    222,911,978.44
       经营活动现金流入小计                      6,723,897,700.76                   6,064,166,409.55
    购买商品、接受劳务支付的现金                4,836,222,058.28                   4,157,464,580.90
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现金                      446,264,801.81                    332,821,582.44
    支付的各项税费                                 149,305,618.18                    379,702,405.28
    支付其他与经营活动有关的现金                   740,669,031.86                    480,722,617.82
       经营活动现金流出小计                      6,172,461,510.13                   5,350,711,186.44
    经营活动产生的现金流量净额                          551,436,190.63                    713,455,223.11二、投资活动产生的现金流量:
    收回投资收到的现金                                                               135,000,000.00
    取得投资收益收到的现金                             4,180,886.60                       5,437,727.16
    处置固定资产、无形资产和其他                    17,810,147.42                         5,355,200.00
                                              19 / 22
                                       梅花生物 2014 年第三季度报告长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
       投资活动现金流入小计                             21,991,034.02                  145,792,927.16
    购建固定资产、无形资产和其他
                                                       306,988,088.05                1,179,749,807.41长期资产支付的现金
    投资支付的现金                                    378,799,948.46                  415,000,000.00
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
       投资活动现金流出小计                            685,788,036.51                1,594,749,807.41
    投资活动产生的现金流量净额                           -663,797,002.49                -1,448,956,880.25三、筹资活动产生的现金流量:
    吸收投资收到的现金                                                              2,457,778,554.00
    其中:子公司吸收少数股东投资收到的现金
    取得借款收到的现金                             5,033,597,907.68                 6,391,013,586.13
    发行债券收到的现金                             2,000,000,000.00
    收到其他与筹资活动有关的现金                      102,106,856.66
       筹资活动现金流入小计                         7,135,704,764.34                 8,848,792,140.13
    偿还债务支付的现金                             6,254,966,481.68                 7,006,161,141.02分配股利、利润或偿付利息支付的现
                                                       604,403,250.55                  615,503,998.08金
    其中:子公司支付给少数股东的股利、利润
    支付其他与筹资活动有关的现金                          8,886,468.00                255,597,137.35
       筹资活动现金流出小计                         6,868,256,200.23                 7,877,262,276.45
    筹资活动产生的现金流量净额                             267,448,564.11                  971,529,863.68四、汇率变动对现金及现金等价物的
                                                        12,818,280.70                  -22,941,716.00影响
    五、现金及现金等价物净增加额                           167,906,032.95                  213,086,490.54
    加:期初现金及现金等价物余额                      557,110,850.67                  580,166,305.18
    六、期末现金及现金等价物余额                           725,016,883.62                  793,252,795.72
    法定代表人:孟庆山                  主管会计工作负责人:李勇刚            会计机构负责人:陶忠
                                                 20 / 22
                                   梅花生物 2014 年第三季度报告
                                  母公司现金流量表
                                    2014 年 1—9 月编制单位:梅花生物科技集团股份有限公司
                                            单位:元          币种:人民币   审计类型:未经审计
                                       年初至报告期期末金额           上年年初至报告期期末金额
              项目
                                            (1-9月)                        (1-9月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                3,901,454,908.64                 1,834,674,678.55
    收到的税费返还
    收到其他与经营活动有关的现金                4,100,214,229.69                 4,549,161,188.49
      经营活动现金流入小计                      8,001,669,138.33                 6,383,835,867.04
    购买商品、接受劳务支付的现金                2,614,523,074.67                 1,431,452,937.14
    支付给职工以及为职工支付的现金                      32,668,759.25                   33,554,403.64
    支付的各项税费                                  31,911,639.66                   28,679,069.72
    支付其他与经营活动有关的现金                6,149,031,095.71                 6,170,618,886.90
      经营活动现金流出小计                      8,828,134,569.29                 7,664,305,297.40
    经营活动产生的现金流量净额                       -826,465,430.96                -1,280,469,430.36二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金                             1,085,010.54                504,068,279.51
    处置固定资产、无形资产和其他
                                                    17,227,762.81                   35,108,200.00长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
      投资活动现金流入小计                          18,312,773.35                  539,176,479.51
    购建固定资产、无形资产和其他
                                                       3,229,832.00                  1,562,371.49长期资产支付的现金
    投资支付的现金                                 296,771,254.58                2,710,000,000.00
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
      投资活动现金流出小计                         300,001,086.58                2,711,562,371.49
    投资活动产生的现金流量净额                       -281,688,313.23                -2,172,385,891.98三、筹资活动产生的现金流量:
    吸收投资收到的现金                                                           2,457,778,554.00
                                             21 / 22
                                     梅花生物 2014 年第三季度报告
    取得借款收到的现金                            1,757,369,182.68                  3,065,000,000.00
    发行债券收到的现金                            2,000,000,000.00
    收到其他与筹资活动有关的现金                  2,831,000,000.00                  4,909,713,444.44
       筹资活动现金流入小计                       6,588,369,182.68                 10,432,491,998.44
    偿还债务支付的现金                            2,697,369,182.68                  3,360,500,000.00
    分配股利、利润或偿付利息支付
                                                     486,680,875.77                   514,780,851.29的现金
    支付其他与筹资活动有关的现金                  2,243,730,317.68                  2,757,093,625.21
       筹资活动现金流出小计                       5,427,780,376.13                  6,632,374,476.50
    筹资活动产生的现金流量净额                        1,160,588,806.55                  3,800,117,521.94四、汇率变动对现金及现金等价物的
                                                               0.01                            -2.31影响
    五、现金及现金等价物净增加额                          52,435,062.37                   347,262,197.29
    加:期初现金及现金等价物余额                     159,206,324.10                   176,130,498.65
    六、期末现金及现金等价物余额                         211,641,386.47                   523,392,695.94
    法定代表人:孟庆山            主管会计工作负责人:李勇刚              会计机构负责人:陶忠4.2 审计报告若季度报告经过注册会计师审计,则附录应披露审计报告正文。□适用√不适用
                                               22 / 22
数据加载中...
prevnext
手机查看股票